Logo image of LGVN

LONGEVERON INC-A (LGVN) Stock Fundamental Analysis

NASDAQ:LGVN - Nasdaq - US54303L2034 - Common Stock - Currency: USD

1.42  -0.08 (-5.33%)

After market: 1.4301 +0.01 (+0.71%)

Fundamental Rating

3

LGVN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. LGVN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LGVN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LGVN had negative earnings in the past year.
In the past year LGVN has reported a negative cash flow from operations.
LGVN had negative earnings in each of the past 5 years.
In the past 5 years LGVN always reported negative operating cash flow.
LGVN Yearly Net Income VS EBIT VS OCF VS FCFLGVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

LGVN has a worse Return On Assets (-122.67%) than 81.15% of its industry peers.
The Return On Equity of LGVN (-149.05%) is worse than 62.30% of its industry peers.
Industry RankSector Rank
ROA -122.67%
ROE -149.05%
ROIC N/A
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
LGVN Yearly ROA, ROE, ROICLGVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

LGVN has a better Gross Margin (82.29%) than 86.53% of its industry peers.
In the last couple of years the Gross Margin of LGVN has grown nicely.
LGVN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
LGVN Yearly Profit, Operating, Gross MarginsLGVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

LGVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LGVN has been increased compared to 1 year ago.
Compared to 5 years ago, LGVN has more shares outstanding
There is no outstanding debt for LGVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LGVN Yearly Shares OutstandingLGVN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M
LGVN Yearly Total Debt VS Total AssetsLGVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -5.99, we must say that LGVN is in the distress zone and has some risk of bankruptcy.
LGVN has a worse Altman-Z score (-5.99) than 64.27% of its industry peers.
There is no outstanding debt for LGVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.99
ROIC/WACCN/A
WACC9.79%
LGVN Yearly LT Debt VS Equity VS FCFLGVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

LGVN has a Current Ratio of 5.61. This indicates that LGVN is financially healthy and has no problem in meeting its short term obligations.
LGVN has a Current ratio of 5.61. This is comparable to the rest of the industry: LGVN outperforms 58.35% of its industry peers.
A Quick Ratio of 5.61 indicates that LGVN has no problem at all paying its short term obligations.
The Quick ratio of LGVN (5.61) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.61
Quick Ratio 5.61
LGVN Yearly Current Assets VS Current LiabilitesLGVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 69.41% over the past year.
The Revenue has grown by 127.51% in the past year. This is a very strong growth!
LGVN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.76% yearly.
EPS 1Y (TTM)69.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.88%
Revenue 1Y (TTM)127.51%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%-30.47%

3.2 Future

The Earnings Per Share is expected to grow by 24.81% on average over the next years. This is a very strong growth
Based on estimates for the next years, LGVN will show a very strong growth in Revenue. The Revenue will grow by 162.69% on average per year.
EPS Next Y67.45%
EPS Next 2Y30.99%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue Next Year-19.95%
Revenue Next 2Y10.12%
Revenue Next 3Y162.69%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LGVN Yearly Revenue VS EstimatesLGVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
LGVN Yearly EPS VS EstimatesLGVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LGVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LGVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LGVN Price Earnings VS Forward Price EarningsLGVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LGVN Per share dataLGVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as LGVN's earnings are expected to grow with 24.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.99%
EPS Next 3Y24.81%

More info and screens

0

5. Dividend

5.1 Amount

LGVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LONGEVERON INC-A

NASDAQ:LGVN (7/11/2025, 8:00:02 PM)

After market: 1.4301 +0.01 (+0.71%)

1.42

-0.08 (-5.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)N/A N/A
Inst Owners8.78%
Inst Owner Change0%
Ins Owners6.72%
Ins Owner Change0.07%
Market Cap21.31M
Analysts82.22
Price Target9.07 (538.73%)
Short Float %3.02%
Short Ratio2.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.89%
Min EPS beat(2)-23.99%
Max EPS beat(2)-1.78%
EPS beat(4)1
Avg EPS beat(4)-26.8%
Min EPS beat(4)-106.22%
Max EPS beat(4)24.81%
EPS beat(8)2
Avg EPS beat(8)-16.49%
EPS beat(12)2
Avg EPS beat(12)-15.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-22.52%
Min Revenue beat(2)-37.77%
Max Revenue beat(2)-7.27%
Revenue beat(4)1
Avg Revenue beat(4)8.31%
Min Revenue beat(4)-37.77%
Max Revenue beat(4)90.89%
Revenue beat(8)2
Avg Revenue beat(8)141.56%
Revenue beat(12)4
Avg Revenue beat(12)100.97%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.14%
PT rev (3m)0.14%
EPS NQ rev (1m)-10.16%
EPS NQ rev (3m)-15.57%
EPS NY rev (1m)-2.94%
EPS NY rev (3m)-8.99%
Revenue NQ rev (1m)-10.34%
Revenue NQ rev (3m)-30.87%
Revenue NY rev (1m)-16.69%
Revenue NY rev (3m)-27.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.58
P/FCF N/A
P/OCF N/A
P/B 1.24
P/tB 1.43
EV/EBITDA N/A
EPS(TTM)-2.94
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS0.15
BVpS1.14
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.67%
ROE -149.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.29%
FCFM N/A
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
F-Score6
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.16%
Cap/Sales 49.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.61
Quick Ratio 5.61
Altman-Z -5.99
F-Score6
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)90.92%
Cap/Depr(5y)89.88%
Cap/Sales(3y)69.8%
Cap/Sales(5y)62.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.88%
EPS Next Y67.45%
EPS Next 2Y30.99%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue 1Y (TTM)127.51%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%-30.47%
Revenue Next Year-19.95%
Revenue Next 2Y10.12%
Revenue Next 3Y162.69%
Revenue Next 5YN/A
EBIT growth 1Y13.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.19%
OCF growth 3YN/A
OCF growth 5YN/A